RecruitingPHASE1, PHASE2NCT06726161

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Studying Burning mouth syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: RayzeBio, Inc.
Principal Investigator: Freddy Escorcia, MD, PhD
RayzeBio, Inc.
Intervention: RYZ811(diagnostic_test)
Enrollment: 590 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2031

Study locations (13)

Research Facility, Birmingham, Alabama, United States
Research Facility, Phoenix, Arizona, United States
Research Facility, Tucson, Arizona, United States
Research Facility, Orange, California, United States
Research Facility, Jacksonville, Florida, United States
Research Facility, Lexington, Kentucky, United States
Research Facility, Baltimore, Maryland, United States
Research Facility, Rochester, Minnesota, United States
Research Facility, Omaha, Nebraska, United States
Research Facility, New York, New York, United States
Research Facility, Houston, Texas, United States
Research Facility, Charlottesville, Virginia, United States
Research Facility, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06726161 on ClinicalTrials.gov

Other trials for Burning mouth syndrome

Additional recruiting or active studies for the same condition.

See all trials for Burning mouth syndrome →

← Back to all trials